This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Law and Medicine  • Drug Therapy, Other  • Alert me on articles by topic

Mike Mitka

JAMA. 2007;297:581.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Passage of a bill on January 12 by the House of Representatives that would allow the government to negotiate with pharmaceutical manufacturers on Medicare's drug prices is a shot across the bow of the White House, signaling that Democrats intend to run Congress differently.

HR 4, the Medicare Prescription Drug Price Negotiation Act of 2007 (http://thomas.loc.gov), repeals the current provision in the Social Security Act prohibiting the Secretary of the Department of Health and Human Services (DHHS) from negotiating lower prices from drug companies for participants in the Medicare Part D prescription drug benefit program. The bill passed by a 255 to 170 margin with 231 Democratic House members voting for the measure along with 24 Republicans. A similar bill (S. 3 ([http://thomas.loc.gov]) is being considered in the Senate.

Rep Nancy Pelosi (D, Calif), the new House Speaker, said the current law has failed . . . [Full Text of this Article]